ALR Technologies said today that the FDA approved the insulin dose adjustment feature of its ALRT diabetes management system.
The ALRT system uses insulin dosing guidelines from the American Association of Clinical Endocrinologists and American Diabetes Association as reference doses. The reference doses are compared with a patient’s current insulin dose to decide if a patient’s insulin dosing regimen is optimal.
If the system notes a difference between the reference dose and the patient’s current dose, it will send a notification to the managing healthcare provider, suggesting a review of the insulin dose. Blood glucose values are uploaded directly from a patient’s blood glucose meter, according to the Richmond, Va.-based company.
The insulin dose adjustment feature is designed for insulin-requiring patients with Type II diabetes. It is not indicated for patients who use insulin pumps, ALR Technologies reported, and it is limited to patients on a fixed dose regimen of insulin.
“With FDA clearance for Insulin Dose Adjustment, it will simplify insulin dosing for healthcare providers,” CEO Sidney Chan said in prepared remarks.
“First, it makes it easy for healthcare providers to titrate insulin dosing for new insulin patients. Second, it will help healthcare providers to prescribe optimal dose(s) for patients on insulin, addressing the so called ‘insulin glass ceiling’. IDA is designed to ensure that patients get an effective and timely dose based on accurate data about their specific needs.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
